Radiopharmaceutical manufacturer SpectronRx and nuclear medicine drug distributor RLS are collaborating in an effort to enhance the supply and availability of diagnostic and therapeutic radiopharmaceuticals.
With the goal of improving production and distribution of the drugs and to help minimize gaps between drug development and manufacturing, SpectronRX will manufacture radiopharmaceutical products for RLS and other partners, according to the companies. RLS will then distribute them.
SpectronRX will also utilize RLS' radiopharmacy network and manufacturing facilities to develop the products in bulk. In turn, RLS will prepare the units into patient-, organ-, and time-specific individual doses, as well as handle local distribution. In addition, SpectronRX will provide additional services related to the manufacture and distribution of the products, including handling quality control and testing as well as regulatory compliance services, the firms said.
SpectronRX and RLS will also collaborate on research and development projects.
